ramucirumab [Ramucirumab]

tematický
1
Termíny

Cyramza

 

1121B
Cyramza
IMC 1121B
IMC-1121B
IMC1121B
LY3009806

Perzistentní odkaz   https://www.medvik.cz/link/D000096662
Definice

Humanizovaná monoklonální protilátka a antagonista receptoru 2 pro vaskulární endoteliální růstový faktor (VEGFR-2).

A humanized monoclonal antibody and antagonist of VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 (VEGFR2).

DUI
D000096662 MeSH Prohlížeč
CUI
M000762505
Historická pozn.
2024 (2009)
Veřejná pozn.
2024; RAMUCIRUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2009-2023

Povolená podhesla

AG
agonisté
AA
analogy a deriváty
AN
analýza
AI
antagonisté a inhibitory
AD
aplikace a dávkování
CS
chemická syntéza
CH
chemie
HI
dějiny
EC
ekonomika
PK
farmakokinetika
PD
farmakologie 1
IM
imunologie
IP
izolace a purifikace
CL
klasifikace
BL
krev
ME
metabolismus
UR
moč
CF
mozkomíšní mok
ST
normy
PO
otrava
AE
škodlivé účinky
TU
terapeutické užití 1
TO
toxicita
RE
účinky záření
SD
zásobování a distribuce

D Chemikálie a léčiva
D12 aminokyseliny, peptidy a proteiny 16
D12.776 proteiny 2 577
D12.776.124 krevní proteiny 909
D12.776.124.486 imunoproteiny 14
D12.776.124.486.485 imunoglobuliny 1 489
D12.776.124.486.485.114 protilátky 1 815
D12.776.124.486.485.114.224 monoklonální protilátky 4 629
D12.776.124.486.485.114.224.060 humanizované monoklonální protilátky 2 790
D12.776.124.486.485.114.224.060.125 abciximab 14
D12.776.124.486.485.114.224.060.250 adalimumab 347
D12.776.124.486.485.114.224.060.313 alemtuzumab 123
D12.776.124.486.485.114.224.060.344 basiliximab 2
D12.776.124.486.485.114.224.060.375 bevacizumab 445
D12.776.124.486.485.114.224.060.438 brentuximab vedotin 40
D12.776.124.486.485.114.224.060.500 certolizumab pegol 47
D12.776.124.486.485.114.224.060.750 cetuximab 185
D12.776.124.486.485.114.224.060.766 daklizumab 6
D12.776.124.486.485.114.224.060.782 denosumab 150
D12.776.124.486.485.114.224.060.790 gemtuzumab 16
D12.776.124.486.485.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.486.485.114.224.060.798 ipilimumab 253
D12.776.124.486.485.114.224.060.813 natalizumab 156
D12.776.124.486.485.114.224.060.829 nivolumab 432
D12.776.124.486.485.114.224.060.844 omalizumab 112
D12.776.124.486.485.114.224.060.860 palivizumab 12
D12.776.124.486.485.114.224.060.864 panitumumab 57
D12.776.124.486.485.114.224.060.866 ramucirumab 1
D12.776.124.486.485.114.224.060.868 ranibizumab 61
D12.776.124.486.485.114.224.060.875 trastuzumab 269
D12.776.124.486.485.114.224.060.937 ustekinumab 121
D12.776.124.790 sérové globuliny 61
D12.776.124.790.651 imunoglobuliny 1 489
D12.776.124.790.651.114 protilátky 1 815
D12.776.124.790.651.114.224 monoklonální protilátky 4 629
D12.776.124.790.651.114.224.060 humanizované monoklonální protilátky 2 790
D12.776.124.790.651.114.224.060.125 abciximab 14
D12.776.124.790.651.114.224.060.250 adalimumab 347
D12.776.124.790.651.114.224.060.375 alemtuzumab 123
D12.776.124.790.651.114.224.060.407 basiliximab 2
D12.776.124.790.651.114.224.060.438 bevacizumab 445
D12.776.124.790.651.114.224.060.469 brentuximab vedotin 40
D12.776.124.790.651.114.224.060.500 certolizumab pegol 47
D12.776.124.790.651.114.224.060.750 cetuximab 185
D12.776.124.790.651.114.224.060.766 daklizumab 6
D12.776.124.790.651.114.224.060.782 denosumab 150
D12.776.124.790.651.114.224.060.790 gemtuzumab 16
D12.776.124.790.651.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.790.651.114.224.060.798 ipilimumab 253
D12.776.124.790.651.114.224.060.813 natalizumab 156
D12.776.124.790.651.114.224.060.829 nivolumab 432
D12.776.124.790.651.114.224.060.844 omalizumab 112
D12.776.124.790.651.114.224.060.860 palivizumab 12
D12.776.124.790.651.114.224.060.864 panitumumab 57
D12.776.124.790.651.114.224.060.866 ramucirumab 1
D12.776.124.790.651.114.224.060.868 ranibizumab 61
D12.776.124.790.651.114.224.060.875 trastuzumab 269
D12.776.124.790.651.114.224.060.937 ustekinumab 121
D12.776.377 globuliny 68
D12.776.377.715 sérové globuliny 61
D12.776.377.715.548 imunoglobuliny 1 489
D12.776.377.715.548.114 protilátky 1 815
D12.776.377.715.548.114.224 monoklonální protilátky 4 629
D12.776.377.715.548.114.224.200 humanizované monoklonální protilátky 2 790
D12.776.377.715.548.114.224.200.125 abciximab 14
D12.776.377.715.548.114.224.200.250 adalimumab 347
D12.776.377.715.548.114.224.200.375 alemtuzumab 123
D12.776.377.715.548.114.224.200.407 basiliximab 2
D12.776.377.715.548.114.224.200.438 bevacizumab 445
D12.776.377.715.548.114.224.200.469 brentuximab vedotin 40
D12.776.377.715.548.114.224.200.500 certolizumab pegol 47
D12.776.377.715.548.114.224.200.750 cetuximab 185
D12.776.377.715.548.114.224.200.766 daklizumab 6
D12.776.377.715.548.114.224.200.782 denosumab 150
D12.776.377.715.548.114.224.200.790 gemtuzumab 16
D12.776.377.715.548.114.224.200.794 inotuzumab ozogamicin 12
D12.776.377.715.548.114.224.200.798 ipilimumab 253
D12.776.377.715.548.114.224.200.813 natalizumab 156
D12.776.377.715.548.114.224.200.829 nivolumab 432
D12.776.377.715.548.114.224.200.844 omalizumab 112
D12.776.377.715.548.114.224.200.860 palivizumab 12
D12.776.377.715.548.114.224.200.864 panitumumab 57
D12.776.377.715.548.114.224.200.866 ramucirumab 1
D12.776.377.715.548.114.224.200.868 ranibizumab 61
D12.776.377.715.548.114.224.200.875 trastuzumab 269
D12.776.377.715.548.114.224.200.937 ustekinumab 121

Přidat